Top news of the week in oncology and cancer drug development.
Hematology
Latest News
Advertisement
CME Content
Advertisement
Researchers found a low-cost approach to examine individual cancer cells, which could lead to a breakthrough in treatments.
Top news of the week in oncology and cancer drug development.
Celgene and Agios will collaborate with a technology company to improve diagnostics for patients with acute myeloid leukemia.
Top news of the day from across the health care landscape.
Patients with memory dysfunctions or depression may be less likely maintain adherence to oral oncoltyics.
Top news of the week from The American Journal of Pharmacy Benefits.
Top news of the week in oncology, and cancer drug development.
Top news of the week in oncology, and cancer drug development.
Top news of the day from across the health care landscape.
Top news of the day from across the healthcare landscape.
Top news of the week in cancer research.
Whether or not cancer cells remain in a cancer patient while undergoing treatment may effect multiple myeloma survival.
DHODH inhibitor caused a reduction in leukemic stem cells and long-term remission in mice.
Pevonedistat shows potential to stop melanoma and other types of cancer.
Top news of the week in oncology, and cancer drug development.
Top news of the day from across the healthcare landscape.
Top news of the week in oncology, and cancer drug development.
Top news of the day from across the healthcare landscape.
Top news of the day from across the health care landscape.
The median charge of treatment for a 6-day hospital stay totals $37,000 in young cancer patients in need of stem cell transplants.
The FDA has expanded the use of Amgen's blinatumomab (Blincyto) to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients.
New treatment for mast cell leukemia could improve quality-of-life and overall survival.
Novel drug is a bispecific T cell engager (BiTE) that targets the B-cell maturation antigen in multiple myeloma.
Factors other than race or ethnicity influence outcomes in multiple myeloma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
2
Study Finds Similar Outcomes Between hMPV and RSV Hospitalizations
3
Higher Ultra-Processed Food Intake Linked to Increased Prediabetes Risk in Young Adults
4
Late-Breaking Data Support Lorundrostat Treatment in Patients With CKD
5
